Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Giuliano, Mario ^a,b,c   Giordano, Antonio ^a,b   Jackson, Summer ^a   Hess, Kenneth R ^a   De Giorgi, Ugo ^a,d   Mego, Michal ^a,e   Handy, Beverly C ^a   Ueno, Naoto T ^a   Alvarez, Ricardo H ^a   De Laurentiis, Michelino ^b   De Placido, Sabino ^b   Valero, Vicente ^a   Hortobagyi, Gabriel N ^a   Reuben, James M ^a   Cristofanilli, Massimo ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^f Fox Chase Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LAPATINIB; NAVELBINE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TUMOR CELL; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CELL CULTURE; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; TUMOR CELL LINE; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84860390470     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2907     Document Type: Article

References (30)

1. Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'Reilly SE, Olivotto IA. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007, 110:973-979. 10.1002/cncr.22867, 17647245.
2. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. J Natl Cancer Inst 2010, 102:456-463. 10.1093/jnci/djq029, 20220104.
3. Andreopoulou E, Hortobagyi GN. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol 2008, 26:3660-3662. 10.1200/JCO.2008.16.1026, 18669447.
4. Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009, 31(Pt 2):2273-2289.
5. Sanchez-Munoz A, Perez-Ruiz E, Jimenez B, Ribelles N, Marquez A, Garcia-Rios I, Alba Conejo E. Targeted therapy of metastatic breast cancer. Clin Transl Oncol 2009, 11:643-650. 10.1007/s12094-009-0419-6, 19828406.
6. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766, 15317891.
7. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430. 10.1200/JCO.2005.08.140, 15735118.
8. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. Cancer 2008, 113:2422-2430. 10.1002/cncr.23852, 18785255.
9. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218-4224. 10.1158/1078-0432.CCR-05-2821, 16857794.
10. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409. 10.1158/1078-0432.CCR-05-1769, 17085652.
11. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009, 27:5153-5159. 10.1200/JCO.2008.20.6664, 19752342.
12. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904. 10.1158/1078-0432.CCR-04-0378, 15501967.
13. Alunni-Fabbroni M, Sandri MT. Circulating tumor cells in clinical practice: methods of detection and possible characterization. Methods 2010, 50:289-297. 10.1016/j.ymeth.2010.01.027, 20116432.
14. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645. 10.1158/1078-0432.CCR-09-2042, 20406831.
15. Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, Saltarelli R, Chiapparino E, Spremberg F, Cristofanilli M, Frati L, Aglianò AM, Gazzaniga P. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011, 22:86-92.
16. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Lohberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010, 124:403-412. 10.1007/s10549-010-1163-x, 20859679.
17. Husband JE, Schwartz LH, Spencer J, Ollivier L, King DM, Johnson R, Reznek R. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004, 90:2256-2260. 2410289, 15150551.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
19. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. 12/02/2008., http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558. 10.1002/sim.1186, 12111919.
21. Barok M, Balazs M, Nagy P, Rakosy Z, Treszl A, Toth E, Juhasz I, Park JW, Isola J, Vereb G, Szöllosi J. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett 2008, 260:198-208. 10.1016/j.canlet.2007.10.043, 18096313.
22. Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004, 10:8185-8194. 10.1158/1078-0432.CCR-03-0094, 15623593.
23. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Androulakis KE, Xyrafas A, Mavroudis D. Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): a pilot randomized phase II study. Proceedings of 2010 ASCO Annual Meeting: June 4-8 2010; Chicago [abstract 547]. J Clin Oncol 2010, 28:15s.
24. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J 2010, 16:327-330. 10.1111/j.1524-4741.2010.00910.x, 20408820.
25. Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, de Cremoux P, Milano G, Pierga JY. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010, 21:1765-1771. 10.1093/annonc/mdq052, 20233745.
26. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009, 2:CD003372.
27. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
28. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247. 10.1200/JCO.2008.21.6457, 20498403.
29. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X, Phan S. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of HER-2 negative locally recurrent or metastatic breast cancer (MBC). Proceedings of 2009 ASCO Annual Meeting: May 29-June 2 2009; Orlando [abstract 1005]. J Clin Oncol 2009, 27:15S.
30. Brufsky A, Bondarenko IN, Smirnov V, Hurvitz S, Perez E, Ponomarova O, Vynnychenko I, Swamy R, Mu H, Rivera R. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium (SABCS) 2009: December 9-13 2009; San Antonio [abstract 42]. Cancer Res 2009, 69:24S.